UW Cancer Center Johnson Creek

Summary

UW Cancer Center Johnson Creek is a medical facility located in Johnson Creek, Wisconsin. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer, Melanoma and other specialties. UW Cancer Center Johnson Creek is involved with conducting 121 clinical trials across 149 conditions. There are 20 research doctors associated with this hospital, such as Kenneth B. De Santes, Nataliya V. Uboha, Kari B. Wisinski, and Dustin Deming, M.D..

Top PIs

Clinical Trials running at UW Cancer Center Johnson Creek

Breast Cancer

Testicular cancer

Pancreatic Carcinoma

Gastric cancer

Lung Cancer

Prostate Cancer

Ovarian Carcinoma

Ovarian Tumors

Testicular Carcinoma

Ovarian Choriocarcinoma

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria